Rapamycin (sirolimus) is a macrolide immunosuppressive and anti-tumor drug. Rapamycin is essentially insoluble in water.
Chen et al. used rapamycin from TOKU-E to study the mammalian target of rapamycin. "AMPA receptor–mTOR activation is required for the antidepressant-like effects of sarcosine during the forced swim test in rats: insertion of AMPA receptor may play a role"
|Mechanism of Action||Rapamycin complexes with FK-binding protein (FKBP12) and inhibits mTOR (FRAP, RAFT), a member of the phosphoinositide kinase-related kinase (PIKK) family.|
|Cancer Applications||Rapamycin suppresses the immune system by preventing T-cell and B-cells from responding to IL-2, a cytokine that would otherwise induce cell proliferation. These properties are especially useful post-transplant to reduce the likelihood of graft rejection. Rapamycin has also demonstrated anti-tumor properties by inducing cellular apoptosis and inhibiting cell division.|
|Solubility||Chloroform: 5 mg/mL|
Methanol: 25 mg/mL
Law, B. K., and Et Al. "Rapamycin: An Anti-cancer Immunosuppressant?" Critical Reviews in Oncology and Hematology 56.1 (2005): 47-60. www.ncbi.gov. Oct. 2005. Web. 30 Aug. 2012.
Dumont, F. J., and Su Q. "Mechanism of Action of the Immunosuppressant Rapamycin." Life Sciences 58.5 (1996): 373-95. www.ncbi.gov. Web. 30 Aug. 2012.